Monday, 18 Nov 2019

You are here

DMARD Success in Myositis-Related Interstitial Lung Disease

It is estimated that up to 50% of patients with idiopathic inflammatory myopathy will be complicated by interstitial lung disease (ILD), and having ILD may impart a poor prognosis. A recent review of the Johns Hopkins myositis-related ILD (M-ILD) cohort has shown that azathioprine (AZA) and mycophenolate mofetil (MMF) use is associated improved lung function and less prednisone use. 

A retrospective study of M-ILD patients seen at Johns Hopkins and treated with AZA or MMF and no other steroid sparing agents were included. They identified a total of 66 AZA treated and 44 MMF treated M-ILD patients.

Treatment with either AZA or MMF lead to improved FVC% and the prednisone lowering over 2-5 years. There was no difference in post-treatment FVC% or DLCO% between groups.

There was a difference in lower prednisone doses at 36 months in the AZA group and in the AZA group only did the DLCO% improve. 

Both AZA and MMF were effective steroid sparing agents capable of improving lung function in M-ILD patients.

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Part 1:  The “P” in Prednisone stands for Poison...and Other Pearls

Everyone has life hacks.  Years of experience and doing the same things repetitively allow us to figure out little tricks to make life easier. A rat in a maze, finding itself at a dead end, will back up and search for a clearing. If this rat encounters its neighbor, it will transmit that information so the second rat won’t make the same mistake.

Protective Effects of ASA and Vasodilators in Systemic Sclerosis

A large cohort study suggests that the use of vasodilators and aspirin (ASA) in systemic sclerosis (SSc) may yield favorable  cardiovascular outcomes.

Myositis Patients at High Risk of Opportunistic Infections

Among patients with systemic rheumatic diseases, the highest incidence of opportunistic infections was seen in those with polymyositis/dermatomyositis (PM/DM), Taiwanese researchers found.

Warfarin Superior to Xarelto in Antiphospholipid Syndrome

A 3 year, multicenter, European, study shows that rivaroxaban was inferior to warfarin in preventing thrombosis in patients with antiphospholipid syndrome (APS) according to the Annals of Internal Medicine. Thus despite the inconvenience of warfarin, it remains the best option for patients with APS.

Declining Trends in Antineutrophil Cytoplasmic Autoantibody–Associated Vasculitis Mortality in the USA

Annals of Internal Medicine reports that age-adjusted mortality rates for antineutrophil cytoplasmic autoantibody–associated vasculitides (AAV) have improved over time - with a decline of nearly 2 percent per year in the United States from 1999 to 2017. Nevertheless, long-term outcomes continue to lag behind mortality rates of the general population.